Adjuvant Development in the context of a vaccine to protect against tuberculosis
$1,170,507N01FY2021AINIH
Vaxine Pty Ltd, Bedford Park
Investigators
Abstract
This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.
View original record on NIH RePORTER →